Use of Generic Antiretroviral Drugs and Single-Tablet Regimen De-Simplification for the Treatment of HIV Infection in Spain

2Citations
Citations of this article
21Readers
Mendeley users who have this article in their library.
Get full text

Abstract

The present study sought to describe the use of generic drugs and single-Tablet regimen (STR) de-simplification for the treatment of human immunodeficiency virus (HIV) infection among 41 hospitals from the cohort of the Spanish HIV/AIDS Research Network (CoRIS). In June 2018, we collected information on when generic antiretroviral drugs (ARVs) were introduced in the different hospitals, how the decisions to use them were made, and how the information was provided to the patients. Most of the nine available generic ARVs in Spain by June 2018 had been introduced in at least 85% of the participating hospitals, except for zidovudine (AZT)/lamivudine (3TC) and AZT. The time difference between the effective marketing date of each generic ARV and its first dispensing date in the hospitals was much shorter for the more recently approved generic ARV since the year 2017. However, only up to 20% of the hospitals de-simplified efavirenz (EFV)/tenofovir disoproxil (TDF)/emtricitabine (FTC), dolutegravir (DTG)/abacavir (ABC)/3TC, and rilpivirine (RPV)/TDF/FTC (to generic EFV+TDF/FTC, DTG+generic ABC/3TC, and RPV+generic TDF/FTC, respectively), whereas the generic STR EFV/TDF/FTC was introduced in 87.8% of the centers. The median times between the date of effective marketing of generic TDF/FTC and the date of de-simplification of EFV/TDF/FTC and RPV/TDF/FTC were 723 [interquartile range (IQR): 369-1,119] and 234 (IQR: 142-264) days, respectively; this time was 155 (IQR: 28-287) days for de-simplification of DTG/ABC/3TC. In conclusion, despite the widespread use of generic ARVs, STRs de-simplification was only undertaken in <20% of the hospitals. There was wide variability in the timing of the introduction of each generic ARV after they were available in the market.

Author supplied keywords

References Powered by Scopus

Economic savings versus health losses: The cost-effectiveness of generic antiretroviral therapy in the United States

121Citations
N/AReaders
Get full text

What do people really think of generic medicines? A systematic review and critical appraisal of literature on stakeholder perceptions of generic drugs

121Citations
N/AReaders
Get full text

The cohort of the spanish hiv research network (coris) and its associated biobank; Organizational issues, main findings and losses to follow-up

115Citations
N/AReaders
Get full text

Cited by Powered by Scopus

A novel approach to state estimation of HIV infection dynamics using fixed-time fractional order observer

3Citations
N/AReaders
Get full text

First-line antiretroviral therapy initiation for newly diagnosed people with HIV in the Netherlands: A retrospective analysis from 2016 to 2020

0Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Ruiz-Algueró, M., Alejos, B., García Yubero, C., Riera Jaume, M., Antonio Iribarren, J., Asensi, V., … Suárez-García, I. (2022). Use of Generic Antiretroviral Drugs and Single-Tablet Regimen De-Simplification for the Treatment of HIV Infection in Spain. AIDS Research and Human Retroviruses, 38(6), 433–440. https://doi.org/10.1089/aid.2021.0122

Readers over time

‘22‘23‘24‘2502468

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 2

50%

Researcher 2

50%

Readers' Discipline

Tooltip

Medicine and Dentistry 2

40%

Nursing and Health Professions 2

40%

Engineering 1

20%

Article Metrics

Tooltip
Social Media
Shares, Likes & Comments: 1

Save time finding and organizing research with Mendeley

Sign up for free
0